In the absence of a submission from the holder of the marketing authorisation, epoetin zeta (Retacrit®) cannot be endorsed for use within NHS Wales for the reduction of exposure to allogeneic blood transfusions in adult non-iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications.